Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ❌ Debt failed
- ❌ P/E failed
- ✅ Correction passed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -22.50%
Price change 2019 → 2020: -46.00%
Price change 2020 → 2021: -47.23%
Price change 2021 → 2022: -6.73%
Price change 2022 → 2023: 69.11%
Price change 2023 → 2024: -29.00%
Price change 2024 → 2025: 119.91%
Price change 2025 → 2026: 73.14%
Price change 2026 (year to date): 78.56%
Financial growth
Revenue CAGR (8 years): 92.32%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 128332000.00
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -20.91
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 19.37% from the high over 6 months.
Correction between 10.0% and 20.0% (target range).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="URGN" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| UroGen Pharma Ltd. | – | – | – | 🔒 |
| BioGaia AB (publ) | 32.7 | 0.01 | +13.3 % | – |
| Clariane SE | 611.5 | 2.16 | +12.4 % | – |
| Nutex Health, Inc. | 6.9 | 1.07 | +54.6 % | – |
| Gerresheimer AG | 31.7 | 1.48 | +5.6 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by UroGen Pharma Ltd. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 11.8 m | -128 m | -1,088.9 % | n/a |
| 2021 | 48.0 m | -111 m | -230.7 % | +307.2 % |
| 2022 | 64.4 m | -110 m | -170.6 % | +34.0 % |
| 2023 | 82.7 m | -102 m | -123.6 % | +28.5 % |
| 2024 | 90.4 m | -127 m | -140.3 % | +9.3 % |
| 2025 | 110 m | -153 m | -139.8 % | +21.4 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Analyst consensus and forecasts
What the financial analysts covering UroGen Pharma Ltd. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Track record against expectations: reported EPS above consensus 3 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in UroGen Pharma Ltd.
Large funds tracked
| Fund | Shares | Value (USD) | Weight in the fund | Change | Quarter |
|---|---|---|---|---|---|
| BlackRock | 3.2 m | 118 m | 0.0 % | +12.5 % | 2026Q2 |
| Morgan Stanley | 2.6 m | 94.8 m | 0.0 % | +0.6 % | 2026Q2 |
| State Street | 2.0 m | 73.8 m | 0.0 % | +129.5 % | 2026Q2 |
| Point72 Asset Management | 1.5 m | 56.1 m | 0.1 % | n/a | 2026Q2 |
| D. E. Shaw & Co | 1.1 m | 42.2 m | 0.0 % | +12.0 % | 2026Q2 |
| Goldman Sachs | 819,834 | 30.2 m | 0.0 % | +37.0 % | 2026Q2 |
| Geode Capital Management | 610,364 | 22.5 m | 0.0 % | +16.5 % | 2026Q2 |
| Bank of America | 475,702 | 17.5 m | 0.0 % | +275.2 % | 2026Q2 |
Latest insider transactions
| Date | Person | Side | Amount |
|---|---|---|---|
| 08/10/2026 | Degnan Chris | sale | 80,791 USD |
| 08/09/2026 | Schoenberg Mark | sale | 37,383 USD |
| 08/09/2026 | Smith Jason Drew | sale | 64,618 USD |
| 20/08/2026 | Schoenberg Mark | sale | 2.9 m USD |
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 20/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about UroGen Pharma Ltd.
What is the UroGen Pharma Ltd. share price?
Latest recorded price: 26.18 USD on 13/11/2026, for a market cap of 1.3 bn USD.
What is the revenue of UroGen Pharma Ltd.?
110 m USD for fiscal year 2025, with net income of -153 m USD (net margin -139.8 %).
What do analysts say about UroGen Pharma Ltd.?
Out of 16 analysts: 12 buy or strong buy, 4 hold, 0 sell or strong sell.
Is UroGen Pharma Ltd. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN IL0011407140).
How many employees does UroGen Pharma Ltd. have?
234 full-time employees according to the latest published profile.
Who runs UroGen Pharma Ltd.?
Elizabeth A. Barrett is the company's chief executive.
Which large funds own UroGen Pharma Ltd.?
As of 2026Q2, among the large funds tracked: BlackRock, Morgan Stanley, State Street, Point72 Asset Management, D. E. Shaw & Co.